+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pembrolizumab"

From
Immune Checkpoint Inhibitors Market - Global Forecast 2026-2032 - Product Thumbnail Image

Immune Checkpoint Inhibitors Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 197 Pages
  • Global
From
Urothelial Cancer Drugs Market - Global Forecast 2026-2032 - Product Thumbnail Image

Urothelial Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • January 2026
  • 196 Pages
  • Global
From
From
From
From
Checkpoint Inhibitor Refractory Cancer Market Report 2025 - Product Thumbnail Image

Checkpoint Inhibitor Refractory Cancer Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
MSI-H and dMMR Market Report 2025 - Product Thumbnail Image

MSI-H and dMMR Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Throat Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Throat Cancer Therapeutics - Global Strategic Business Report

  • Report
  • February 2026
  • 267 Pages
  • Global
From
Gastric Cancer Market - Global Strategic Business Report - Product Thumbnail Image

Gastric Cancer Market - Global Strategic Business Report

  • Report
  • February 2026
  • 582 Pages
  • Global
From
Oral Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Oral Cancer Therapeutics - Global Strategic Business Report

  • Report
  • February 2026
  • 182 Pages
  • Global
From
Metastatic Cancer Drugs Market - Global Strategic Business Report - Product Thumbnail Image

Metastatic Cancer Drugs Market - Global Strategic Business Report

  • Report
  • February 2026
  • 377 Pages
  • Global
From
From
Stomach Cancer Treatment Market - Global Strategic Business Report - Product Thumbnail Image

Stomach Cancer Treatment Market - Global Strategic Business Report

  • Report
  • February 2026
  • 371 Pages
  • Global
From
Hepatocellular Carcinoma Drugs - Global Strategic Business Report - Product Thumbnail Image

Hepatocellular Carcinoma Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 198 Pages
  • Global
From
Gynecological Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 193 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • February 2026
  • 224 Pages
  • Global
From
Immune Checkpoint Inhibitors - Global Strategic Business Report - Product Thumbnail Image

Immune Checkpoint Inhibitors - Global Strategic Business Report

  • Report
  • February 2026
  • 194 Pages
  • Global
From
Urothelial Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Urothelial Cancer Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 126 Pages
  • Global
From
Loading Indicator

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers. Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated. Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more